New pompe disease drug moves to first human tests
NCT ID NCT06109948
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new drug called ABX1100 in 46 people, including healthy volunteers and patients with late-onset Pompe disease. The main goal was to check safety and how the drug moves through the body. Researchers gave single or multiple doses to find the right amount for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain Metabolism Study Using PET/fMRI (NCT05756335)
- Short-term arm immobilization & muscle metabolis NCT06750497
- Parent-led app boosts kids' motor & brain skills NCT07680075
- DigiKids App-Based Motor Skills Trial for Kids (NCT07679633)
- QX-4533 Safety Study in Healthy People | NCT07678463
- Pomegranate Supplement & Gut Health in Alcohol L NCT07678567
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lysosomal and Rare Disorders Research and Treatment Center, Inc
Fairfax, Virginia, 22030, United States
-
MAGIC clinic
Calgary, Alberta, Canada
-
McMaster University
Hamilton, Ontario, Canada
-
UCI
Orange, California, 92868, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States